- Business Wire•3 hours agoFDA Grants Priority Review for Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis
Genentech, a member of the Roche Group , announced today that the U.S. Food and Drug Administration has accepted the company’s Supplemental Biologics License Application for Actemra® for the treatment of GCA, a chronic, potentially life-threatening autoimmune condition.
- Investor's Business Daily•3 days ago
Roche, Merck and Pfizer will likely disappoint on 2017 guidance, but AbbVie stock remains a "top pick" for Jefferies analyst Jeffrey Holford.
RHHBY : Summary for ROCHE HLDG LTD SPONS - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||28.93 - 29.22|
|52 Week Range||25.25 - 33.77|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||22.54|
|Dividend & Yield||1.02 (3.49%)|
|1y Target Est||N/A|